Initial Invasive or Conservative Strategy for Stable Coronary Disease.
David J MaronJudith S HochmanHarmony R ReynoldsSripal BangaloreSean M O'BrienWilliam E BodenBernard R ChaitmanRoxy SeniorJose López-SendónKaren P AlexanderRenato D LopesLeslee J ShawJeffrey S BergerJonathan D NewmanMandeep S SidhuShaun G GoodmanWitold RuzylloGilbert GosselinAldo Pietro MaggioniHarvey D WhiteBalram BhargavaJames K MinG B John ManciniDaniel S BermanMichael H PicardRaymond Y KwongZiad A AliDaniel B MarkJohn A SpertusMangalath N KrishnanAhmed ElghamazNagaraja MoorthyWhady A HuebMarcin DemkowKreton MavromatisOlga BockeriaJesus PeteiroTodd D MillerHanna SzwedRolf DoerrMatyas KeltaiJoseph B SelvanayagamP Gabriel StegClaes HeldShun KohsakaStavroula MavromichalisRuth KirbyNeal O JeffriesFrank E HarrellFrank W RockholdSamuel BroderickT Bruce FergusonDavid O WilliamsRobert A HarringtonGregg W StoneYves Rosenbergnull nullPublished in: The New England journal of medicine (2020)
Among patients with stable coronary disease and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of ischemic cardiovascular events or death from any cause over a median of 3.2 years. The trial findings were sensitive to the definition of myocardial infarction that was used. (Funded by the National Heart, Lung, and Blood Institute and others; ISCHEMIA ClinicalTrials.gov number, NCT01471522.).
Keyphrases